Molecular markers are especially important for the molecular classification of glioma subtypes.26IDH mutations diagnostic for WHO-recognized diffuse glioma disease ontologies were detected in 19.0% (IDH1) and 0.2% (IDH2) of gliomas. Here, IDH2 is linked to central nervous system cancer.